Patel Engineering bags hydropower project worth Rs 239.98 crore from NHPC
Located in the South District of Sikkim, the project has a scheduled completion timeline of 18 months. The scope of work includes the construction of the tunnel spillway, gate operation chamber and shaft, precast bridge, access road, dyke, energy dissipation structures, and an environmental flow tunnel.
Kavita Shirvaikar, Managing Director, stated, 'We are honoured to receive the LOA from NHPC for this strategically important hydro power project. Our deep experience in the North Eastern region positions us strongly to execute this project with precision and efficiency. This win is another step toward our vision of contributing meaningfully to India's clean energy future.'
PEL is already executing NHPC's Teesta-VI HEP (Lot-2) project near Singtam, around 30 km from this new site, reinforcing its foothold in the region and underscoring its expertise in delivering complex hydro infrastructure.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
EaseMyTrip signs MoU with Timbuckdo to redefine student travel in India
By Aman Shukla Published on July 24, 2025, 09:54 IST EaseMyTrip, one of India's leading and fastest-growing online travel platforms, has entered into a strategic partnership with Timbuckdo, a rising social commerce platform focused on students. The two companies have signed a Memorandum of Understanding (MoU) to revolutionize student travel across India by offering exclusive, curated discounts on flights, bus tickets, hotel stays, and unique travel experiences. This collaboration blends EaseMyTrip's robust travel infrastructure with Timbuckdo's strong student network, aiming to make travel more affordable, accessible, and aspirational for Gen Z. By integrating EaseMyTrip's services into Timbuckdo's student-focused marketplace, the partnership promises a seamless booking experience tailored specifically for students. The alliance will also include on-ground campus activations, student travel festivals, and campaigns led by youth influencers to boost awareness and engagement across colleges and universities. Timbuckdo is targeting over one million student bookings in the next 12 months, reflecting the massive potential of India's student travel market, which is expected to cross USD 10 billion by 2027. Through this initiative, EaseMyTrip and Timbuckdo are positioning themselves at the forefront of youth mobility, catering to the aspirations of a new generation of Indian travelers. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
an hour ago
- Business Upturn
Dr. Reddy's shares jump over 3% following Q1 results – Should you buy, hold or sell? Know More
By Aditya Bhagchandani Published on July 24, 2025, 09:37 IST Shares of Dr. Reddy's Laboratories surged 3.06% to Rs 1,285.60 on Wednesday after the company reported its Q1 FY26 financial results. The stock touched an intraday high of Rs 1,287.90 and now commands a market capitalization of Rs 1.07 lakh crore. For the quarter ended June 30, 2025, the pharmaceutical major posted a consolidated net profit of Rs 1,418 crore, up 2% year-on-year. Revenue from operations stood at Rs 8,545 crore, reflecting an 11% YoY increase, primarily driven by contributions from the acquired Nicotine Replacement Therapy (NRT) portfolio and steady performance in branded markets. However, profit declined 11% quarter-on-quarter, while revenue remained flat sequentially. EBITDA for the quarter was Rs 2,280 crore, marking a 5% YoY increase, though EBITDA margin slipped 530 basis points to 56.9%, largely due to pricing pressure in the US generics segment and lower operating leverage. The Global Generics segment recorded Rs 7,560 crore in revenue, up 10% YoY, but remained unchanged QoQ. Revenue from North America declined 11% YoY to Rs 3,410 crore amid price erosion in key generics like Lenalidomide. Meanwhile, India revenue grew 11% YoY to Rs 1,470 crore, aided by new launches and pricing strategies. European business saw a sharp 142% YoY jump to Rs 1,270 crore, driven by the NRT acquisition and product launches. Brokerages offered a cautious outlook on Dr. Reddy's Laboratories following its Q1 FY26 results, primarily due to concerns over the US generics business. CLSA and Jefferies both retained their 'Underperform' ratings, with target prices of Rs 1,120 and Rs 1,100 respectively. CLSA noted that while overall earnings were in line with expectations, the US base business is expected to remain flat or grow in low single digits year-on-year, with Revlimid sales likely tapering off from Q3FY26. Jefferies flagged a miss in Q1 estimates due to a sharper-than-expected decline in US sales, driven by lower revenues from gRevlimid and sustained pressure in the base portfolio. Elevated SG&A and R&D spending also weighed on margins. However, it highlighted upcoming launches such as gOzempic in Canada and the US filing for Abatacept as key triggers to watch. Meanwhile, Morgan Stanley maintained an 'Equal-weight' rating with a target price of Rs 1,298, acknowledging steady growth in most markets but citing generic price erosion and reduced operating leverage as drag factors on margin. Dr. Reddy's Q1 YoY Comparison Table (in Rs crore): Metric Q1 FY26 Q1 FY25 YoY % Change Revenue from Operations 8,545 7,700 11% Net Profit 1,418 1,390 2% EBITDA 2,280 2,170 5% EBITDA Margin (%) 56.9% 62.2% -530 bps Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
an hour ago
- Business Upturn
Cigniti Technologies shares drop 5% as Q1 net profit falls 10% QoQ to Rs 65.9 crore
By Aman Shukla Published on July 24, 2025, 09:37 IST Shares of Cigniti Technologies fell around 5% in morning trade on Thursday after the company announced its Q1 FY26 results, which showed only a marginal revenue growth and a dip in net profit. As of 9:36 AM, the shares were trading 5.10% lower at Rs 1,653.30. The company's consolidated revenue came in at Rs 534 crore, just 0.8% higher than the previous quarter's Rs 530 crore. Operating profit (EBIT) stayed largely unchanged at Rs 81.5 crore, with margins holding steady at 15.3%. However, the drag came from the bottom line, as net profit declined nearly 10% QoQ to Rs 65.9 crore, down from Rs 73.2 crore in the previous quarter. While the company has managed to maintain healthy margins, the muted growth and profit slip seem to have weighed on investor sentiment. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
